Synlogic reports SYNB8802 Phase 1b proof of concept: -38% urinary oxalate reduction in enteric hyperoxaluria

SYNLOGIC, INC.

SYNB8802 reduced urinary oxalate by 38% vs placebo at 3x10^11 TID dose in Roux-en-Y gastric bypass patients.
No serious adverse events; GI AEs mild and similar in frequency between active and placebo groups.
Third positive clinical readout for Synlogic in 2022, following SYNB1934 for PKU and SYNB1353 for homocystinuria.
Company to host webcast today at 8:30 AM ET with Dr. Kyle Wood of UAB.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.